Christina Poh, M.D.

(877) 460-4673
Christina Poh, M.D.
Hematologist-Oncologist
Clinical Expertise

Hematology

Lymphoma

Other Languages Spoken
Thai
Academic Appointments
  • Associate Clinical Professor, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation
  • Director, T Cell Lymphoma Program

Christina Poh, M.D., is an associate clinical professor in the Division of Lymphoma and the director of the T Cell Lymphoma Program at City of Hope® Cancer Center Duarte. She works with patients diagnosed with all types of lymphoma but specializes in the rare and aggressive subtype known as T-cell lymphoma.

A compassionate provider, Dr. Poh is also a seasoned researcher who has served as principal investigator on numerous trials and studies and is published widely in her field. She also holds leadership roles with multiple national committees and consortiums on lymphoma treatment.

Dr. Poh earned her medical degree and completed her internship at Loma Linda University School of Medicine in California. She then pursued a fellowship in hematology and oncology, with a focus on cancer genomics, at the University of California, Davis. Before joining City of Hope, she led the T Cell lymphoma program at University of Washington/Fred Hutchinson Cancer Center in Seattle. She has also participated in volunteer efforts at home and abroad, including taking part in relief initiatives after the 2004 Asian tsunami.

Location

Education & Experience

Degrees

  • 2014, Doctor of Medicine, Loma Linda University School of Medicine, Loma Linda, CA
  • 2010, Bachelor of Science, Neuroscience, University of Rochester, Rochester, NY

Residency

  • 2017, Internal Medicine, Loma Linda University Health, Loma Linda, CA

Fellowship

  • 2020, Hematology and Oncology, University of California Davis, Davis, CA

Professional Experience

  • 2025-present, Associate Clinical Professor, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
  • 2025-present, Director, T Cell Lymphoma Program, City of Hope, Duarte, California
  • 2023-2025, Assistant Professor of Medicine, Fred Hutchinson Cancer Center, Seattle, WA
  • 2020-2023, Clinical Assistant Professor of Medicine, Fred Hutchinson Cancer Center, Seattle, WA

Awards & Memberships

Awards

  • March 2026-June 2029, Clinical Investigator Career Development Award
    • Lymphoma Research Foundation
    • Project: Advancing First-Line Therapy for Nodal T-Follicular Helper Cell Lymphoma $375,000 over 3 years
  • March 2024-October 2026, Lymphoma Scientific Research Mentoring Program
    • Stephanie A. Gregory Distinguished Scholar Lymphoma Research Foundation
    • Project: Decitabine/Cedazuridine and Tolinapant Maintenance after First-Line Therapy for PTCL $10,000 over two years
  • December 7, 2019, Young Investigator Award - Chinese American Hematologist and Oncologist Network
  • December 5, 2019, American Society of Hematology (ASH) Abstract Achievement Award: Upper Extremity Deep Vein Thrombosis in Acute Leukemia and Non-Hodgkins Lymphoma: Analysis of the California Cancer Registry

Memberships

  • American Society of Hematology
  • SWOG Cancer Research Network, Lymphoma Committee
  • European Hematology Association
  • Hoosier Cancer Research Network

Publications

Full List of Published Work

  • Sehn LH, Hubel K, Luminari S, Scholz CW, Salar A, Paneesha S, Whalin BE, Panayiotidis P, Lee, HP, Ubieto AJ, Sancho JM, Kim TM, Domenech ED, Kumode T, Poh C, Thieblemont C, Deeren D, de Wit E, Arbushites M, Vassallo I, Trneny M. Tafasitamab, Lenalidomide and Rituximab in Relapsed or Refractory Follicular Lymphoma: a Global, Phase 3 Randomised Controlled Trial (inMIND). Lancet 2025; Dec 5:S0140-6736(25)01778-7. doi: 10.1016/S0140-6736(25)01778-7. Epub ahead of print. PMID: 41360064.
  • Poh C, Chen X, Voutsinas JM, Warren EH, Shadman M, Lynch RC, Till BG, Ujjani CS, Di M, Raghunathan V, Smith SD, Wu QV, Cherian S, Gopal AK. Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia. Br. J. Haematol. 2025; Impact of immunophenotype on clinical disease characteristics and outcomes in T‐cell prolymphocytic leukemia
  • Poh C, Voutsinas JM, Shadman M, et al. Pralatrexate Is Effective in Cytotoxic Cutaneous T-cell Lymphomas. Blood Adv. Published online June 17, 2025. doi:10.1182/bloodadvances.2025016680
  • Goyal A, O'Leary D, Dabaja B, Weng WK, Zain J, Cutler C, Guitart J, Kim YH, Geskin LJ, Hoppe RT, Wilson LD, Beaven AW, Horwitz S, Allen PB, Barta SK, Bohjanen K, Brammer JE, Carter JB, Comfere N, DeSimone JA, Dusenbery K, Duvic M, Huen A, Jagadeesh D, Kelsey CR, Khodadoust MS, Lechowicz MJ, Mehta-Shah N, Moskowitz AJ, Olsen EA, Poh C, Pro B, Querfeld C, Sauter C, Sokol L, Sokumbi O, Wilcox RA, Zic JA, Hamadani M, Foss F. ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome. Transplant Cell Ther. 2024 Aug 31:S2666-6367(24)00621-3. doi: 10.1016/j.jtct.2024.08.020.
  • Gajzer DC, Chen X, Sabath DE, Poh C, Naresh KN. Does a subset of mature T-cell leukemias with features akin to T-cell prolymphocytic leukemia but lacking rearrangement of the TCL1 represent peripheral T-cell lymphoma, NOS in a leukemic phase? EJHaem. 2024; 1-5. doi: 10.1002/jha2.953.
  • Banerjee R, Poh C, Hirayama AV, Gauthier J, Cassaday RD, Shadman M, Cowan AJ, Till BG, Green DJ, Kiem HP, Gopal AK, Maloney DG. Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic. Blood Adv. 2024 Jan 10:bloodadvances.2023012336. doi: 10.1182/bloodadvances.2023012336.
  • Lynch RC, Ujjani CS, Poh C, Warren EH, Smith SD, Shadman M, Till BG, Raghunathan V, Alig S, Alizadeh AA, Gulhane A, Chen D, Tseng Y, Coye H, Shelby M, Ottemiller S, Keo S, Verni K, Du H, Vandermeer J, Gaston A, Rasmussen H, Martin P, Marzbani E, Voutsinas JM, Gopal AK. Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma. Blood. 2023; blood.2022019254. doi: 10.1182/blood.2022019254.
  • Lynch RC, Poh C, Ujjani CS, Warren EH, Smith SD, Shadman M, Morris K, Lee S, Rasmussen H, Ottemiller S, Shelby M, Keo S, Verni K, Kurtz DM, Alizadeh AA, Chabon JJ, Hogan GJ, Schulz A, Gooley T, Voutsinas JM, Gopal AK. Polatuzumab vedotin with infusional chemotherapy (Pola- DA-EPCH-R) for untreated aggressive B-cell non-Hodgkin lymphomas. Blood Adv. 2023 Jun 13;7(11):2449-2458. doi:10.1182/bloodadvances.2022009145.
  • Poh C, Mcpherson JD, Tuscano J, Li Q, Parikh-Patel A, Vogel C,
    Cockburn M, Keegan T. Environmental Pesticide Exposure and non-Hodgkin Lymphoma Survival: A Population-Based Study. BMC Med. 2022; 20(165). doi: 10.1186/s12916-022-02348-7.
  • Poh C, Arora M, Ghuman S, Tuscano J. Belinostat Use in
    Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia. Acta Haematol. 2021; 144(1): 91-95.
  • Poh C, Brunson A, Keegan T, Wun T, Mahajan A. Incidence of Upper Extremity Deep Vein Thrombosis in Acute Leukemia and Effect on Mortality. TH Open. 2020; 4: e309-317
  • Poh C, Keegan T, Rosenberg A. Secondary Primary Malignancies in Multiple Myeloma: A Review. Blood Rev. 2020 Sep 6:100757. doi: 10.1016/j.blre.2020.100757